Threshold Pharmaceuticals, Inc (THLD): Opiniones

que ha pasao en Ziop hoy?¿?

Y a tapar el hueco juas

Han cancelado su investigación sobre sarcoma

ZIOP (competencia THLD)

joder, me acabo de conectar , la anterior vez estaba en pre, como un cohete, y hora la veo casi en el mismo sitio.
La próxima subida, venderé las que tenga verdes, y entonces será la buena y ya no bajará a por mí.
THLD

Ha cerrado el hueco en 4.81 , ahora UP, UP

Vamos quemando etapas, ya no tenemos la excusa de ZIOP. A ver si de una vez nos dejan subir.

Acabo de verlo, pero yahoo dice que el minimo ha sido 4.83
Yo las he largado a 5.
Ahora parece que sube...

http://seekingalpha.com/currents/post/910051?source=email_rt_mc_readmore

Threshold Pharmaceuticals (THLD +1.3%) gains on the back of Ziopharm's (ZIOP -63%) earlier announcement that it's ending Phase 3 trials of palifosfamide after it failed to meet its primary endpoint. An article posted in Seeking Alpha last Friday infers that THLD's competing drug, TH-302, although similar to palifosfamide in molecular structure, is differentiated enough in nature that there is still sufficient reason to believe it could work. Now, with ZIOP's drug out of the running, TH-302's addressable market increases significantly. The company is due to release data from its own Phase III study early next year.

TH-302's addressable market increases significantly = HAY QUE RECALCULAR PRECIOS OBJETIVOS SEÑORES!!!

THRESHOLD NOW THE LEADER

que bonitas palabras ....

http://seekingalpha.com/article/1300991-ziopharm-fails-phase-iii-trial-threshold-now-the-leader?source=email_rt_article_readmore